BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The Company Pharmacia Enterprises S.A. submitted on 12 March 2001 an application for Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Somavert,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur: Dr. Eric Abadie 
Co-Rapporteur: 
Dr. Gonzalo Calvo Rojas 
Orphan Medicinal Product: 
Somavert  was  designated  as  orphan  medicinal  product  EU/3/01/023  on  14  February  2001  in  the 
following indication: treatment of acromegaly. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 29 March 2001. 
During  the  meeting  on  26-28  June  2001  the  CPMP  adopted  the  Rapporteur’s  and  the  EMEA 
Secretariat’s proposal that no inspection(s) or sampling and testing had to be carried out before 
the assessment of Somavert is complete. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 5 July 2001 
(Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members 
on 12 July 2001 (Annex 2) 
During the meeting on 17-18 July 2001 the Biotechnology Working Party agreed in their report 
to the CPMP on the main quality issues following initial assessment to be included in the List of 
Questions (Annex 3). 
During the meeting on 24-26 July 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the Company. The final consolidated List of Questions was sent to the Company on 
26 July 2001 (Annex 4). 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  28 
January 2002. 
The  response  Assessment  Report  on  the  company’s  responses  to  the  List  of  Questions  was 
circulated to all CPMP members on 4 April 2002 (Annex 5). 
During the meeting on 23-25 April 2002 the CPMP adopted a List of Outstanding Issues to be 
addressed during an oral explanation and in writing (Annex 6). 
The company submitted the responses to the CPMP List of Outstanding Issues on 28 May 2002. 
During  the  meeting  on  25-27  June  2002,  the  CPMP  requested  a  GMP  inspection  for  the 
manufacturing site for the active substance: Diosynth RTP, Inc. 
The response Assessment Report on the company’s responses to the List of Outstanding Issues 
was circulated to all CPMP members on 1 July 2002 (Annex 7). 
The company submitted their responses to remaining issues on 15 July 2002. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
• 
• 
During the meeting on 23-25 July 2002 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Pharmacia Enterprises S.A. on 25 July 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 13 November 2002. 
2/2 
EMEA 2004 
 
 
 
